Examples of using Frequency grouping in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Thus, the frequency grouping is categorised as not known.
The following ADRs were reported during clinical trials with GANFORT within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Frequency grouping Very common• Leucopaenia Neutropaenia Grade 3 19.3%; Grade 4 6.
Within each MedDRA system organ class and frequency grouping, undesirable effects are presented in order of decreasing incidence.
Ris The adverse reactions reported by the investigator as at least possibly related to fondaparinux are presented within each frequency grouping very common≥ 1/ 10; common:≥ 1/ 100 to< 1/ 10;
Within each frequency grouping, ADRs are presented in the order of decreasing seriousness.
Each term is presented in its most common category only and within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
For adverse reactions identified from post-marketing experience with Tygacil derived from spontaneous reports for which the frequency cannot be estimated, the frequency grouping is categorized as not known.
Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Table 1 presents the adverse reactions that have been reported during clinical studies with GANFORT(within each frequency grouping, adverse reactions are presented in order of decreasing seriousness) or in the post-marketing period.
Within each frequency grouping in Table 1, adverse reactions are presented in decreasing order of seriousness.
Table 1 presents the adverse reactions that were reported during a 12-week clinical study of GANFORT single-dose(within each frequency grouping, adverse reactions are presented in order of decreasing seriousness) or in the post-marketing period.
Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Table 5 Summary of relatedADRs reported in patients treated with Xeloda in combination treatment in addition to those seen with Xeloda monotherapy or seen at a higher frequency grouping compared to Xeloda monotherapy Body System.
Within each frequency grouping and SOC, adverse reactions are presented in the order of decreasing seriousness.
Table 5 Summary of related ADRs reported inpatients treated with capecitabine in combination treatment in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy.
Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent first.
The adverse reactions considered to be at least possibly-related to treatment from clinical studies were as follows frequencies defined as: very common≥ 1/ 10, common≥ 1/ 100 to< 1/ 10,uncommon≥ 1/ 1,000 to< 1/ 100; within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Within each frequency grouping, adverse reactions are presented in order of decreasing incidence and seriousness.
The following related adverse reactions were listed below by system organ class and within each frequency grouping, adverse reactions are presented in order of decreasing seriousness: common(≥ 1/ 100 to< 1/ 10); uncommon(≥ 1/ 1,000 to< 1/ 100); rare≥ 1/ 10,000 to< 1/ 1,000.
Within each frequency grouping, undesirable effects observed during treatment or within 30 days following the completion of treatment with MabCampath are presented in order of decreasing seriousness.
Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness.
Within each frequency grouping in the tables below, undesirable effects are presented in decreasing order of seriousness.
Within each frequency grouping and system organ class, adverse reactions are presented in order of decreasing seriousness.
Within each frequency grouping and system organ class, adverse reactions are presented in order of decreasing seriousness.
Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent first.
Within each frequency grouping, adverse reactions are listed using MedDRA terminology and presented in order of decreasing seriousness.
Within each frequency grouping, ADRs are presented in order of decreasing severity and were reported using NCI-CTCAE v 4.0(common toxicity criteria) for assessment of toxicity.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common> 1/ 10, common> 1/ 100,< 1/10, uncommon> 1/ 1000,< 1/ 100.